Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Not stated
- Not stated
- Nov 22, 2024
Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.
Or read the full text and all 3 standing review criteria here, free with an account. Create free account
Summary
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias…
Related NIH announcements
NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
$500k
NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
$6.3M
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 3 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
$500k